Scopus
YÖKSİS Eşleşti
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · Ekim 2021
YÖKSİS Kayıtları
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · 2021 SCI-Expanded
PROFESÖR FATMA HÜMEYRA YERLİKAYA AYDEMİR →
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis.
International immunopharmacology · 2021 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · 2021 SCI-Expanded
PROFESÖR SEDAT ABUŞOĞLU →
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · 2021 SCI-Expanded
DOÇENT GÜLSÜM ABUŞOĞLU →
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · 2021 SCI-Expanded
PROFESÖR FATMA HÜMEYRA YERLİKAYA AYDEMİR →
Altered kynurenine pathway metabolism in patients with ankylosing spondylitis
International Immunopharmacology · 2021 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Makale Bilgileri
DergiInternational Immunopharmacology
Yayın TarihiEkim 2021
Cilt / Sayfa99
Scopus ID2-s2.0-85111720803
Özet
Background: Various studies reported that increased proinflammatory cytokines in patients with ankylosing spondylitis (AS). Proinflammatory cytokines can affect the expression of various kynurenine pathway enzymes and therefore lead to metabolic changes that can affect the inflammatory response and immunity. Our aim was to measure serum levels of kynurenine pathway metabolites in patients with AS. Methods: The study included 85 patients with AS and 50 healthy volunteers. Serum tryptophan, kynurenine, kynurenic acid, 3-hydroxyanthranilic acid, 3-hydroxykynurenine, quinolinic acid concentrations were measured with tandem mass spectrometry. In addition, participants were divided into four groups according to the treatment regimen: TNF-α inhibitor group, conventional therapy group, control group and newly diagnosed AS group. These groups were compared in terms of kynurenine pathways metabolites, interleukin 6 (IL-6), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. Results: Serum tryptophan, kynurenic acid, 3-hydroxykynurenine levels were significantly decreased (p < 0.05) in both AS groups compared to the control group, while the levels of kynurenine, quinolinic acid, CRP, ESR, and IL-6 were higher (p < 0.05). The Kynurenine/Tryptophan ratio and CRP levels of the conventional therapy and anti-TNF therapy group were significantly lower than the newly diagnosed AS patients (p < 0.05). Conclusion: As a result of our study, we found that altered kynurenine pathway metabolism in patients with AS. Conventional therapy and anti-TNF-α therapy are effective in reducing the Kynurenine/Tryptophan ratio and CRP levels, although the effect of both treatments on other metabolites appears to be limited.
Yazarlar (9)
1
Duygu Eryavuz Onmaz
ORCID: 0000-0001-8564-1824
2
Abdullah Sivrikaya
3
Kevser Isik
4
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
5
Ilknur Albayrak Gezer
6
Fatma Humeyra Yerlikaya
7
Gulsum Abusoglu
8
Ali Ünlü
ORCID: 0000-0002-9991-3939
9
Dilek Tezcan
ORCID: 0000-0002-8295-9770
Anahtar Kelimeler
Ankylosing spondylitis
Inflammation
Kynurenine
Tryptophan
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
14
Atıf
9
Yazar
4
Anahtar Kelime